Ann Arbor’s NanoBio may buck hurdles in life science research

Life sciences are expected to have a number of hurdles in the coming years due to the tightening of FDA rules and regulations. Ann Arbor’s NanoBio, however, maybe be able to jump those with the amount of capital they’ve seen and their communication with the FDA. Excerpt: Capital is flowing to NanoBio, which announced July 8 that it had received $10 million in venture capital from two separate funding sources. The firm has managed to secure $22 million in capital this year – enough to last the company at least two years, a critical buffer in a tough fundraising and regulatory atmosphere. The firm received its latest funding from New York-based majority shareholder Perseus and Venture Investors, which has an Ann Arbor office. “It was a bigger round than we initially planned, but it was welcome because of the (financial) environment and it gives us a little bit of extra runway,” Peralta said. Nanoemulsion technology is relatively new to the industry. That means the FDA likely would put NanoBio’s drug therapies under intense scrutiny before issuing market approval. Read the entire article here.